dm+d
Unassigned
New Medicines
Relapsed or refractory marginal zone lymphoma
Information
New molecular entity
Incyte
Incyte
Development and Regulatory status
Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials
Category
A phosphatidylinositol 3-kinase-δ inhibitor
There are around 14,100 new non-Hodgkin lymphoma cases in the UK every year [1]. Marginal zone lymphomas (MZLs) account for between 5% and 17% of all NHL. MZLs consist of 3 different subtypes with extranodal being the most commonly reported, representing 50-70% of MZL, followed by splenic (20%) and nodal (10%) [2].
Relapsed or refractory marginal zone lymphoma
Oral